Live at IDWeek 2015

Review: Diagnosis, Treatment of C. difficile in Adults

A single infusion of the human monoclonal antibody bezlotoxumab (BEZ), with or without actoxumab (ACT), improves prevention of recurrent C. difficile infection (rCDI), according to a presentation at IDWeek 2015 of data combined from the double-blind, randomized Phase 3 MODIFY I and MODIFY II studies.